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Abstract 
Objective. Glutamine has been proposed as a preventive treatment for toxicity related to cancer therapies. The aim of 
this study was to test the efficacy of glutamine in the prevention of radiation enteritis. 
Methods. A randomized, double-blind, controlled trial was performed including 69 patients who were assigned to 
receive either glutamine (Gln, 30 g/d) or placebo while they were receiving abdominal radiotherapy. Patients were re-
evaluated 1 y after completion of treatment. The presence of chronic enteritis was assessed using the Radiation 
Therapy Oncology Group scale. Nutritional status was evaluated using subjective global assessment, weight, and 
bioimpedance. Relative risk (RR) and its confidence interval (CI) were also calculated. 
Results. The trial initially included 69 patients (34 Gln, 35 placebo), but 11 patients were lost during follow-up (4 
Gln, 7 placebo; P = 0.296). Chronic enteritis was developed by 14 % of patients: Gln 16.7 % versus placebo 11.1% 
(RR = 1.33; 95 % CI, 0.35–5.03; P = 0.540). Most cases of enteritis were grade I (75 %), with no differences between 
groups. The stool frequency increased after radiotherapy in patients who received Gln (from 1 ± 1 to 2 ± 2 stools per 
day, P = 0.012), but remained unchanged with placebo (1 ± 1 stools per day, P = 0.858; difference between groups 
P = 0.004). There were no differences between the two groups in terms of weight, fat mass, or fat-free mass index, or 
between patients with enteritis and those without intestinal toxicity. 
Conclusions.Chronic enteritis is a relatively infrequent phenomenon, and Gln administration during radiotherapy 
does not exert a protective effect. 
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Introduction 
Radiation-induced tissue damage is a complex process in which oxidative stress, inflammation, cellular 
apoptosis, and genetic changes are involved. The acute toxicity caused by radiotherapy (RT) may be 
observed during exposure, lasts >1–2 mo, and is caused by the loss of functional, replicating cells. 
Chronic injury is the consequence of the loss of parenchymal cells and the alteration of microcirculation 
in the irradiated organ, changes that produce fibrosis and loss of function in organs, and which typically 
appear months to years after exposure [1]. Factors such as radiation dose and mode of administration, 
sensitivity of organs to radiation, the volume of irradiated tissue, concomitant treatments (e.g., 
chemotherapy), and some patient characteristics (e.g., age), influence the development of toxicity 
following RT [2]. More than 50 % of patients who receive pelvic RT may subsequently suffer 
gastrointestinal (GI) symptoms, such as diarrhea, that compromise quality of life. Radiation-induced 
diarrhea has many causes, including bacterial overgrowth, changes in bowel transit, malabsorption, 
psychological factors, and medications [3]. 
Glutamine (Gln) may protect the gut during RT by means of its particular functions. Glutamine 
contributes to intestinal trophism, is the precursor of glutathione (a key molecule in the antioxidant 
chain), modulates the inflammatory response, protects cells from various insults by producing heat-shock 
proteins, and also influences apoptosis [4] and [5]. Few studies have assessed the effects of Gln on 
radiation enteritis [6], [7], [8] and [9]. A previous trial showed an increase in the number of cases of acute 
diarrhea in patients receiving Gln during RT compared with placebo [10]. The hypothesis of this study 
was that the biological effects of Gln could prevent the development of either acute or chronic radiation 
enteritis. The aim of the present study was to assess the development of chronic radiation enteritis in the 
population recruited in this previous trial.  
Methods and participants 
The methodology followed in this trial was reported previously [10]. Briefly, a randomized controlled, 
double-blind study was designed to compare the effectiveness of Gln versus placebo in the prevention of 
radiation enteritis. The study was evaluated by the local Research Ethics Committee, which confirmed 
that it followed the Declaration of Helsinki, and was registered with Clinical Trials (ref. no. 
NCT00828399). 
Participants 
Inclusion criteria included being age >18 y and undergoing abdominal or pelvic RT due to a neoplasm in 
that location, independent of other cancer treatments (surgery, chemotherapy, or brachytherapy). 
Exclusion criteria included a life expectancy <1 y, short bowel syndrome, intestinal diseases (e.g., 
inflammatory bowel disease, celiac disease, or Whipple disease), moderate or severe chronic kidney 
disease, and the inability to receive either oral medication or to understand the information provided. All 
patients signed an informed consent document. The treatment group received supplementation with 
30 g/d of oral Gln (Glutamina NM©, Nutrición Médica, Madrid) and the control group received a placebo 
(supplementation of 30 g/d of whole casein, Proteína NM©, Nutrición Médica, Madrid) beginning 3 d 
before starting RT until completion of the antitumoral treatment. Researchers did not modify the patients' 
dietary habits; rather, patients followed their usual diet including protein amount and sources. 
Chronic radiation enteritis assessment 
In this phase of the study, patients were re-evaluated 1 y post-RT. At that time, they were asked about the 
number and characteristics of stools, and intestinal toxicity was classified according to the criteria of the 
Radiation Therapy Oncology Group (RTOG): grade 0 (no diarrhea), grade I (5 stools per day, abdominal 
cramping, scarce bleeding), grade II (>5 stools per day, rectal mucus, intermittent bleeding), grade III 
(intestinal obstruction or bleeding that requires surgery), and grade IV (necrosis, perforation, or fistula). 
Nutritional assessment 
Nutritional status was evaluated using the Subjective Global Assessment (SGA). Anthropometry included 
the measurement of height and body weight, body mass index (BMI), dynamometry (Smedlay's Dynamo 
Meter©, Tokyo, Japan), and the determination of fat-free mass (FFM) and fat mass by bioelectrical 
impedance (Tanita Body Composition Analyzer TBF-300©). The fat-free mass index (FFMI) was 
calculated by dividing an individual's FFM by the square of their height (kg/m2). 
Statistical analysis 
The normality of quantitative variables was assessed using the Kolmogorov-Smirnov test. Those variables 
with a normal distribution were summarized as the mean and SD and compared using the paired Student's 
t test. Quantitative variables without a normal distribution were summarized by the median (Md) and 
interquartile range (IQR), and compared using Mann-Whitney's U-test. Categorical variables were 
summarized as percentages and compared using the χ2 test. Relative risk (RR) and its 95 % confidence 
interval (CI) were also calculated. 
Results 
Sixty-nine patients were originally recruited for the trial, however, only 57 could be reassessed 1 y after 
the end of RT (Fig. 1). The participants had received a daily dose of Gln of 0.4 (0.1) g/kg (minimum 
0.3 g/kg, maximum 0.6 g/kg). No differences were found between the characteristics of the initial group 
of patients and those that completed the follow-up (Table 1). 
  
 
 
 
Fig. 1. Flowchart of the study. The recruitment included 69 of the 88 patients initially invited to participate in the study. All the 
recruited patients were randomized and included in the intention-to-treat analysis. Three patients in the glutamine group and eight in 
the placebo group were lost during follow-up. RT, radiotherapy. 
Table 1. Patient characteristics 
 Initial group (N = 69) Group after 1 y (N = 57) P-value 
    
Age (y) 64.9 ± 9.7 63.6 ± 6.9 0.382 
Sex (male) (%) 64.7 61.4 0.794 
Pathology (%)    
Urologic cancer 47.1 43.9 0.597 
Gynecologic cancer 23.5 28.1  
Rectal cancer 20.6 22.8  
Other tumors 8.8 5.2  
Radiation dose (Gy) 50.4 ± 33 50.4 ± 33 1.000 
Chemotherapy (%) 44.1 38.6 0.710 
Previous surgery (%) 32.4 33.3 0.894 
Brachytherapy (%) 23.5 28.1 0.674 
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Stool characteristics 
Patients in both groups reported a stool frequency of once per day (Md, IQR = 1) before RT. After 1 y, 
the patients who had received Gln reported two stools per day (Md, IQR = 1). Those who were 
randomized to the placebo group reported one stool per day (Md, IQR = 1). The increase in stool 
frequency in the Gln group was significant (P = 0.01), as was the difference between the two groups at 
1 y (P = 0.004). In the Gln group 56.7 % experienced changes in intestinal movements with respect to 
before RT versus 40.7 % in the placebo group (P = 0.230). There were no differences in the frequency of 
patients with liquid or soft stools between the Gln and placebo groups: 26.7 % (8 of 30) versus 11.1% (3 
of 27), respectively, P = 0.137. However, more patients in the former group reported changes in stool 
consistency: 33.3 % (10 of 30) versus 7.4 % (2 of 27), P = 0.020. 
Chronic radiation enteritis 
Chronic enteritis was present in 14 % (n = 8) of the patients. Most cases were grade I intestinal toxicity 
(75 %, n = 6), with one patient each suffering from grade II (12.5 %) or grade IV (12.5 %) toxicity 
according to the RTOG criteria. In the Gln group 16.7 % presented diarrhea (n = 5) versus 11.1% (n = 3) 
in the placebo group (P = 0.540). The severity of chronic enteritis was similar between groups, with most 
cases being grade I (Gln 60 % versus placebo 100 %, P = 0.600). The RR for the development of chronic 
enteritis in patients who received Gln during RT was 1.33 (CI 95 %, 0.35–5.03). When subgroups of the 
different types of tumor were analyzed, there were no differences according to the treatment received ( 
Fig. 2). The RR of chronic enteritis was 1.57 for urologic tumours (CI 95 %, 0.16–5.16), 17 for 
gynecologic tumors (CI 95 %, 0.06–4.70), and 0.58 for rectal cancer (CI 95 %, 0.07–4.95). 
 
 
 
Fig. 2. Prevalence of chronic radiation enteritis according to type of tumor. 
Nutritional status 
During the administration of RT, most patients maintained weight and FFM, and few patients developed 
malnutrition (three with Gln, two with placebo), as a result of a stable energy and protein intake [10]. One 
year later, according to the SGA, one patient in the placebo group was malnourished; none of the patients 
in the Gln group were malnourished (P = 0.288). There were no differences between patients in terms of 
anthropometry ( Table 2).  
Table 2. Comparison of Anthropometric parameters among groups 
 Glutamine Placebo P-value Chronic enteritis No chronic enteritis P-value 
       
BMI (kg/m2) 28.9 ± 4.2 27.3 ± 4.5 0.176 29.9 ± 5.1 27.9 ± 4.2 0.225 
Weight change (%) 1.0 ± 6.6 2.9 ± 4.4 0.206 1.6 ± 6.4 1.9 ± 5.6 0.891 
Fat mass (%) 32.4 ± 6.6 31.9 ± 7.4 0.783 34.0 ± 6.7 31.9 ± 7.0 0.431 
FFMI (kg/m2) 19.4 ± 2.1 18.4 ± 2.2 0.078 19.3 ± 2.0 18.8 ± 2.2 0.544 
Handgrip strength (kg) 31.4 ± 8.5 29.2 ± 5.5 0.253 25.8 ± 5.3 31.1 ± 7.4 0.058 
       
 
BMI, Body mass index; FFMI, fat-free mass index 
None of the patients with chronic enteritis was diagnosed as malnourished by SGA versus only one of 
those without intestinal toxicity (P = 0.648). Patients with chronic enteritis presented similar nutritional 
parameters as patients without toxicity ( Table 2). 
Discussion 
To our knowledge, this is the first randomized, double-blind, controlled trial to evaluate the effects of the 
administration of oral Gln during RT on chronic radiation enteritis. During RT, more cases of acute 
diarrhea were found among patients who had received Gln than in those patients who received placebo 
[10]. One year later, patients who were randomly allocated to receive 30 g/d of Gln during RT presented 
significant changes in stool frequency and consistency. Nevertheless, there were no differences in the 
diagnosed cases of chronic enteritis according to RTOG criteria. 
The different criteria for the diagnosis of diarrhea and radiation enteritis hinder comparison of the 
prevalence of this complication between studies. The interval between RT and evaluation also could 
influence its prevalence. Most studies reported a wide range of prevalence of between 5 % and 60 % [11], 
[12], [13], [14] and [15]. This study found a prevalence of chronic enteritis near the lower limit, a fact that 
could be explained by the restrictive definition of diarrhea in the RTOG criteria (≥5 stools per day) and 
the relatively short time after RT. Furthermore, about 50 % of patients reported changes in stool 
frequency and 33 % in stool consistency. 
Previously, only one study has observed the effects of Gln during RT on chronic enteritis. In this 
open-label, non controlled cohort study, 32 patients received 30 g/d of oral Gln during RT until 4 wk after 
completion of treatment, and 26 patients received no treatment. The former group had lower rates of acute 
(28 % versus 61 %) and chronic diarrhea (3.8 % versus 15.6 %) than the latter group, although the authors 
did not provide the statistical significance of these results [9]. 
Regarding the effects of Gln on acute radiation enteritis, two randomized controlled, double-blind 
trials have been published in full to date. The first included patients with pelvic cancer, and found no 
differences in the development of acute toxicity. The second included patients with rectal cancer, and 
found that 64.3 % of those treated with Gln had acute enteritis compared with 53 % in the placebo group, 
although this difference was not significant [7] and [8]. None of the studies evaluated the patients several 
months after RT. Two studies have shown possible beneficial effects of Gln during pelvic RT. The first 
study recruited patients with prostate cancer who received either 21 g/d Gln or placebo. Glutamine 
treatment was associated with less tissue damage in the rectum, but not with better clinical outcomes [6]. 
The second study has already been commented on, and described a lower incidence of acute radiation 
enteritis with Gln treatment [9]. 
The mechanisms by which Gln may exacerbate the intestinal toxicity of radiation remain unclear. In 
rats, arginine has been related to increased radiation-induced damage of the colon [16]. This damage 
appears to be induced by the production of nitric oxide. Glutamine can directly promote the generation of 
this molecule by macrophages under stress conditions, and indirectly by the pathway Gln-citrulline-
arginine [17]. Glutamine also can regulate collagen production, and thereby modulate the healing of 
irradiated tissue [18]. In rats, Gln supplementation prevents acute changes in extracellular matrix and 
collagen expression in the urinary bladder after exposure to radiation, but the effects on fibrosis have not 
been studied [19]. The same amino acid increases the transcription of the collagen gene in skin 
fibroblasts, suggesting that the type of tissue and stimulus may influence the effects of glutamine [20]. 
The analysis of tissue sample probably would have proportionated more information about the intestinal 
damage in both groups, but these samples were not obtained due to ethical restrictions. Finally, this is not 
the first study showing adverse effects related to the administration of glutamine. The REDOX (Reducing 
Deaths due to OXidative Stress) trial, in which critically ill patients received Gln, showed an increased 
mortality related to the administration of high doses of this amino acid [21]. 
The study we present is involved in several controversies within the field of clinical nutrition, the first 
of which was the selection of a placebo. In our trial, casein, a protein obtained from milk, was selected for 
its nutritional composition and its lack of other possible effects on health. Other studies used 
maltodextrin, but it resulted in a comparison between a protein-enriched diet and a carbohydrate-enriched 
diet. Other amino acids used in trials, like glycine, have antioxidant effects like Gln [22]. A whole protein 
was considered a suitable, although not perfect, comparator. It should be noted that Gln is present in all 
protein foods, although represents <10 % of the amino acid content of casein [23]. The appropriate dose 
of Gln for each clinical condition is also unclear. Previous studies evaluating its effects on patients 
receiving RT have administered 30 g/d, and this dose has been safely tried in critically ill patients [24], 
[25], [26] and [27]. Additionally, lower doses (0.15 g/kg) than the used in this study (0.4 g/kg) did not 
promote glutathione in women receiving chemotherapy [28]. Following this background, 30 g was the 
selected dose of treatment, and a similar amount of protein of placebo. Nevertheless, Gln dosage may be 
the key to understanding the results of this study, as the amount of Gln contained in diet may modulate 
gut inflammation. Rats receiving a medium dose of the amino acid developed less bowel inflammation 
than those with a higher dose or a Gln-free diet [29]. 
The prevalence of malnutrition was low in both groups in this study, as well as among patients with 
chronic enteritis. Anthropometric data remained unchanged 1 y after the completion of RT. This may 
reflect the limited nutritional effects of the mild and infrequent GI symptoms that were found. 
Malnutrition has been found in more than half of patients with more severe grades of enteritis (i.e., those 
who require surgery) [30]. However, all patients who developed acute radiation enteritis during the first 
phase of the trial received nutritional counseling for the relief of toxicity, which may have helped to 
prevent the deterioration in nutritional status. Some studies have demonstrated that dietary manipulations, 
such as restriction of fat or fiber, can reduce GI symptoms and prevent weight loss during RT, but there is 
a lack of strong evidence about these kinds of interventions [31]. 
This study has some limitations that should be considered. First, the sample size was calculated for the 
detection of differences between groups regarding acute diarrhea but not for chronic enteritis. This fact, in 
addition to the loss of patients during the follow-up period, reduces the statistical power of the study. 
Second, it was not possible to evaluate the development of chronic intestinal toxicity in patients lost to 
follow-up, although their initial characteristics were similar to those who completed the study. Third, the 
researchers were aware of the treatment that the patients had received during RT, so the assessment 1 y 
after RT was not double-blind. Finally, biochemical markers of intestinal function (e.g., citrulline) or 
inflammation (e.g., calprotectin) could not be measured, and the assessment of toxicity was performed 
using only the symptoms and signs that the patients reported. 
Conclusion 
This trial demonstrated that the administration of the usual dose of oral Gln during abdominal or pelvic 
RT was associated with an increase in stool pass frequency and changes in stool consistency 1 y after 
completion of treatment. These results, in addition to the lack of effect on acute radiation enteritis, 
suggests that the use of this amino acid in patients with abdominal or pelvic tumors treated with RT is not 
useful to attenuate the intestinal symptoms induced by the treatment. 
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